Cargando…
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials
PURPOSE: Identifying factors associated with treatment alteration (treatment discontinuation and dose reduction) may help to attain the treatment goals for metastatic breast cancer. The value of changes in the quality of life (QOL) in predicting treatment alteration remained unclear. This study aime...
Autores principales: | Kawahara, Takuya, Iwamoto, Takayuki, Takashima, Ikumi, Hanazawa, Ryoichi, Uemura, Kohei, Uemura, Yukari, Mukai, Hirofumi, Kikawa, Yuichiro, Taira, Naruto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512887/ https://www.ncbi.nlm.nih.gov/pubmed/35857127 http://dx.doi.org/10.1007/s00520-022-07283-0 |
Ejemplares similares
-
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
por: Kawahara, Takuya, et al.
Publicado: (2022) -
Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial
por: Narui, Kazutaka, et al.
Publicado: (2022) -
Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: Miyahara, Kana, et al.
Publicado: (2022) -
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017) -
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
por: Kikawa, Yuichiro, et al.
Publicado: (2022)